Healthcare / BiotechnologyNasdaqCM
$2.19
-0.04 (-1.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.3M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-471.4%
↓Gross Margin
71.3%
↑Debt/Equity
0.93
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
-997.0%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.0M · net income $-13.4M · FCF $-10.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $1.0M | $1.0M | $9784.00 | $2.8M | $10.0M | $0.00 | — | — | — | — | $766000.00 | — | $80000.00 | $6000.00 | $625000.00 |
| Net Income | $-13.4M | $-13.4M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-27.4M | $-14.3M | $-16.7M | $-11.5M | $-672687.00 | $-39.6M | $-23.3M | $-17.1M | $-22.1M |
| EBITDA | $-11.9M | $-11.9M | $-23.4M | $-30.9M | $-31.4M | — | — | — | — | — | $-369591.00 | — | — | — | — |
| EPS | -1.20 | -1.20 | -0.48 | -4.15 | -4.44 | -7.56 | -10.92 | — | — | — | — | — | — | — | — |
| Gross Margin | 71.3% | 71.3% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1315.5% | -1315.5% | -239692.2% | -1101.9% | -313.9% | — | — | — | — | — | -82.3% | — | — | — | — |
| Net Margin | -1300.7% | -1300.7% | -41430.9% | -1074.2% | -309.5% | — | — | — | — | — | -87.8% | — | -29177.5% | -285716.7% | -3536.2% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.93 | 0.93 | -0.22 | -0.28 | 0.04 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.03 | 1.03 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-10.3M | $-10.3M | $4.9M | $-39.5M | $-18.2M | $-28.8M | $-25.3M | $-13.3M | $-10.3M | $-2.5M | — | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -471.4% | -471.4% | 67.4% | 597.5% | -278.5% | -99.8% | 2379.1% | -3235.7% | -248.8% | -86.5% | 94.7% | 84337.7% | -51.5% | 18.2% | 27.6% |
| Valuation | |||||||||||||||
| P/B | 8.61 | 8.61 | — | — | 7.42 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 10429.4% | 10429.4% | -99.7% | -71.9% | — | — | — | — | — | — | — | — | 1233.3% | -99.0% | — |
| EPS Growth | -150.0% | -150.0% | 88.4% | 6.5% | — | 30.8% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.48 → -1.20
Residual
-26.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.